SCHEMBL7322109

SCHEMBL7322109

COc1ccc(S(=O)(=O)Nc2ccc(C)cc2C(=O)O)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 3/20 0.73
FFAR4 Q5NUL3 1/20 0.69
CYP2C9 P11712 3/20 0.68
CYP1A2 P05177 1/20 0.68
KEAP1 Q14145 2/20 0.65
NFE2L2 Q16236 2/20 0.65
POLB P06746 1/20 0.58
CYP2C19 P33261 1/20 0.58
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 2/20 0.57
RCE1 Q9Y256 1/20 0.57
LMNA P02545 2/20 0.56
TP53 P04637 1/20 0.56
HPGD P15428 1/20 0.56
HTT P42858 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
KCNA5 P22460 1/20 0.55
TSHR P16473 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12200967 0.92 CYP2C9 (0.76) METAP2FFAR4CYP2C9CYP1A2KEAP1
SCHEMBL5955445 0.90 CYP2C9 (0.84) METAP2FFAR4CYP2C9CYP1A2KEAP1
SCHEMBL7316092 0.90 CYP2C9 (0.68) METAP2FFAR4CYP2C9CYP1A2KEAP1
SCHEMBL12570805 0.89 METAP2 (0.86) METAP2CYP2C9CYP1A2POLBCYP2C19
SCHEMBL14075396 0.88 CYP2C9 (0.73) METAP2FFAR4CYP2C9CYP1A2KEAP1
SCHEMBL16479406 0.87 LMNA (0.68) METAP2FFAR4CYP2C9CYP1A2KEAP1
SCHEMBL10249221 0.86 ACLY (0.67) METAP2KEAP1NFE2L2ALDH1A1LMNA
SCHEMBL3512984 0.85 CYP2C9 (0.90) METAP2FFAR4CYP2C9CYP1A2KEAP1
SCHEMBL2009251 0.85 METAP2 (1.00) METAP2CYP2C9CYP1A2ALDH1A1LMNA
SCHEMBL23200290 0.84 CYP2C9 (0.76) METAP2FFAR4CYP2C9CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025930-A1 SMALL MOLECULE INHIBITORS SELECTIVE FOR POLO-LIKE KINASE PROTEIN UNIVERISTY OF SOUTH CAROLINA 2024-01-25 US disclosed
US-20200399297-A1 Small Molecule Inhibitors Selective for Polo-Like Kinase Proteins UNIVERSITY OF SOUTH CAROLINA 2020-12-24 US disclosed
EP-0938471-B1 THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS AMERICAN CYANAMID CO (US) 2001-12-12 EP disclosed
CN-1240429-A Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors AMERICAN CYANAMID CO (US) 2000-01-05 CN disclosed
US-5929097-A INHIBIT TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME AMERICAN CYANAMID COMPANY (US) 1999-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025930-A1 SMALL MOLECULE INHIBITORS SELECTIVE FOR POLO-LIKE KINASE PROTEIN PLK2, PLK4, PLK3 METAP2 3732/4885FFAR4 3848/4885CYP2C9 4652/4885
US-20200399297-A1 Small Molecule Inhibitors Selective for Polo-Like Kinase Proteins PLK2, PLK4, PLK3 METAP2 3688/4885FFAR4 3955/4885CYP2C9 4669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.